Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06749210 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

DAANCE FOR CHEMOTHERAPY-INDUCED NEUROPATHY

Study acronym: DAANCE
StatusRecruiting
PhasePhase 2
Started2025-02-19
View on ClinicalTrials.gov ↗

Amendment history

2025-11-03
Study Status, Contacts/Locations v4
Study sites1→2
2025-07-15
Study Status, Oversight v3
Primary completion date2025-08-15→2029-08-15
Completion date2025-08-15→2029-08-15
2025-03-13
Not Yet Recruiting→Recruiting Study Identification, Study Status, Oversight, Contacts/Locations v2
Trial statusNot Yet Recruiting→Recruiting
Primary completion date2030-09→2025-08-15
Completion date2030-09→2025-08-15
Start dateestimated 2025-01→confirmed 2025-02-19
Study sitesdetails revised at 1 of 1 site
2025-01-02
Study Identification, Study Status, Oversight, Contacts/Locations v1
Primary completion date2028-12→2030-09
Completion date2029-08→2030-09
Start date2024-12→2025-01
Study sitescontacts updated at 1 of 1 site
Study titlerevised
DAANCE forFOR CHEMOTHERAPY-INDUCED NEUROPATHY
2024-12-19
Original filing
Up to 80% of breast cancer survivors experience chemotherapy-induced neuropathy that impairs quality of life and increases fall risk long into survivorship, yet treatment options for neuropathy remain limited. The successful treatment will target neurophysiologic mechanisms for restoring function while addressing patient-reported symptoms and participation in treatment. Toward this end, the investigators propose to study a noninvasive, social sensorimotor intervention - Adapted Argentine Tango - which targets motor control restoration, symptom alleviation, and treatment participation in concert.
Trial Details
NCT Number NCT06749210
Lead Sponsor Ohio State University Comprehensive Cancer Center
Collaborators: National Institute on Aging (NIA), Yale University, Emory University
Conditions Cancer of the Breast, Chemotherapy-induced Neuropathy
Enrollment 140 participants
Start Date 2025-02-19
Primary Completion 2029-08-15 (estimated)
Study Completion 2029-08-15 (estimated)
Updated on ClinicalTrials.gov 2025-11-05